Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular T...(ere licensed in early 2006 from CyDexPha...),Health

Date:1/5/2009

ere licensed in early 2006 from CyDex Pharmaceuticals (http://www.cydexpharma.com). NEXTERONE is based on the CyDex patent-protected CAPTISOL(R) technology platform. Prism and CyDex are also developing a novel injectable form of the blockbuster antiplatelet agent PLAVIX(R) (clopidogrel) for use in acute care situations overcoming the limitations of the current product which is only available as an oral therapy.

For further information, visit http://www.prismpharma.com.

NEXTERONE(R) is a registered trademark of Prism Pharmaceuticals, Inc. Cordarone(R) and PLAVIX(R) are registered trademarks of sanofi-aventis.

'/>"/>

SOURCE Prism Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes